Cardiogeni (AQSE:CGNI) LT-Debt-to-Total-Asset: 0.00 (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cardiogeni LT-Debt-to-Total-Asset?

Cardiogeni AQSE:CGNI LT-Debt-to-Total-Asset is 0.00 as of . 20.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Cardiogeni's long-term debt to total assests ratio for the quarter that ended in . 20 was 0.00.

Cardiogeni's long-term debt to total assets ratio stayed the same from . 20 (0.00) to . 20 (0.00).

Cardiogeni  (AQSE:CGNI) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Cardiogeni LT-Debt-to-Total-Asset Related Terms

Cardiogeni LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Cardiogeni's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiogeni LT-Debt-to-Total-Asset Chart

Cardiogeni Annual Data
Trend
LT-Debt-to-Total-Asset

Cardiogeni Semi-Annual Data
LT-Debt-to-Total-Asset

Cardiogeni LT-Debt-to-Total-Asset Calculation

Cardiogeni's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in . 20 is calculated as

LT Debt to Total Assets (A: . 20 )=Long-Term Debt & Capital Lease Obligation (A: . 20 )/Total Assets (A: . 20 )
=/
=

Cardiogeni's Long-Term Debt to Total Asset Ratio for the quarter that ended in . 20 is calculated as

LT Debt to Total Assets (Q: . 20 )=Long-Term Debt & Capital Lease Obligation (Q: . 20 )/Total Assets (Q: . 20 )
=/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Cardiogeni (AQSE:CGNI) has a LT-Debt-to-Total-Asset of 0.00 as of . 20. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Cardiogeni and its competitors.
Is Cardiogeni's LT-Debt-to-Total-Asset too high?
Cardiogeni's current LT-Debt-to-Total-Asset is 0.00.
How does Cardiogeni's LT-Debt-to-Total-Asset compare to ?
Cardiogeni's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Cardiogeni and its competitors. Cardiogeni's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiogeni stock overvalued right now?
Cardiogeni (AQSE:CGNI) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Cardiogeni (AQSE:CGNI), the current LT-Debt-to-Total-Asset is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cardiogeni Business Description

Comparable Companies
Address Celixir House Stratford-Upon-Avon Business & Technology Park, Innovation Way, Stratford upon Avon, GBR, CV37 7GZ
Cardiogeni PLC is engaged in the development and commercialisation of a portfolio of novel cellular medicines for heart failure. The Company focuses on the development and commercialisation of novel cellular medicines targeting early- and mid-stage heart failure. Its strategic priority is to complete a pivotal Phase 2b/3 study and obtain first market approval for its product, CLXR-001, in a suitable jurisdiction, and then establish strategic funding and collaboration agreements to develop and commercialise the product in the US, EU, Japan, and other jurisdictions.